-
Two cases were reported in this paper. the first case was a 52-year-old wildlife biologist who went deer hunting in Virginia in November 2008.
-
As reported here in 2003, the World Bank began funding a project to train giant pouched Gambian rats to sniff out tuberculosis (TB) in sputum specimens in sub-Saharan Africa. Rats have been successfully trained to target landmines, and using a similar training/reward technique, pilot data suggested that rats could be trained to detect TB in respiratory specimens.
-
In this issue: Statins and liver function; dosing timing for thyroxine; rivaroxaban for VTE, DVT, and stroke; echinacea and the common cold; and FDA actions.
-
A randomized, double-blind, placebo-controlled trial of the efficacy of oral amoxicillin-clavulanate treatment (40 mg amoxicillin + 5.7 mg clavulanate/kg/day divided into 2 daily doses for 7 days) of acute otitis media was conducted among children 6-35 months of age in Finland.
-
In intensive-care units, death attributable to infections caused by multidrug-resistant bacteria, especially Pseudomonas aeruginosa and Acinetobacter baumannii species, is a common occurrence.
-
-
New research shows that despite nearly three decades of safe sex and clean needle messages and HIV prevention work, a large proportion of people at risk for HIV infection continue to engage in high-risk behaviors.
-
A new model HIV/AIDS prevention program uses a group skills-building and peer-group led model to build on HIV clinicians' risk reduction messages to disadvantaged women who are HIV positive.
-
AIDS Alert asked Mark Ishaug, president and chief executive officer of the newly-formed AIDS United of Washington, DC, to discuss why the National AIDS Fund and the national policy advocacy group AIDS Action merged and what this will mean for people living with HIV/AIDS and the clinicians providing their care. His answers are presented below in a question-and-answer (Q&A) format.
-
On Dec. 22, 2010, the Food and Drug Administration approved a new 200 mg etravirine (Intelence®) tablet. Etravirine was originally approved in 2008, in only a 100 mg tablet formulation. The new 200 mg dosage form can help reduce pill burden for patients taking Intelence.
